Infliximab in acute severe colitis: getting the right dose

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Acute severe colitis is a critical condition necessitating immediate intravenous corticosteroid administration.
• Infliximab serves as a crucial rescue therapy for patients with ulcerative colitis (UC) who do not respond to initial corticosteroid treatment.
• Understanding infliximab's pharmacokinetics is vital for optimizing treatment in this patient population.

Purpose of the Study:

• To review the altered pharmacokinetics of infliximab in the context of acute severe ulcerative colitis.
• To summarize recent data on accelerated infliximab dosing regimens for acute severe colitis.

Main Methods:

• Literature review of published data on infliximab pharmacokinetics in acute severe UC.
• Analysis of studies investigating accelerated dosing strategies for infliximab in this patient group.

Main Results:

• Pharmacokinetics of infliximab are significantly altered in patients with acute severe UC.
• Accelerated infliximab dosing shows promise in improving treatment response rates.

Conclusions:

• Altered infliximab pharmacokinetics in acute severe UC necessitate consideration of optimized dosing.
• Accelerated infliximab dosing represents a potential advancement in managing steroid-refractory acute severe colitis.